201 related articles for article (PubMed ID: 17464308)
21. Retinal toxicity of indocyanine green in albino rabbits.
Goldstein M; Zemel E; Loewenstein A; Perlman I
Invest Ophthalmol Vis Sci; 2006 May; 47(5):2100-7. PubMed ID: 16639021
[TBL] [Abstract][Full Text] [Related]
22. Rapid infusion rituximab changing practice for patient care.
Al Zahrani A; Ibrahim N; Al Eid A
J Oncol Pharm Pract; 2009 Sep; 15(3):183-6. PubMed ID: 19171551
[TBL] [Abstract][Full Text] [Related]
23. Clinical review: treatment of vitreoretinal lymphoma.
Pe'er J; Hochberg FH; Foster CS
Ocul Immunol Inflamm; 2009; 17(5):299-306. PubMed ID: 19831557
[TBL] [Abstract][Full Text] [Related]
24. Micropulsed laser photocoagulation and intravitreal triamcinolone acetonide injection for the treatment of retinal angiomatous proliferation.
Roth DB; Scott IU; Gloth JM; Green SN; Yarian DL; Wheatley M
Retina; 2007; 27(9):1201-4. PubMed ID: 18046225
[TBL] [Abstract][Full Text] [Related]
25. Retinal toxicity of intravitreal kenalog in albino rabbits.
Lang Y; Zemel E; Miller B; Perlman I
Retina; 2007; 27(6):778-88. PubMed ID: 17621190
[TBL] [Abstract][Full Text] [Related]
26. Treatment of primary intraocular lymphoma (PIOL) has involved systemic, intravitreal or intrathecal chemotherapy and/or radiotherapy.
Itty S; Olson JH; O'Connell DJ; Pulido JS
Retina; 2009 Mar; 29(3):415-6. PubMed ID: 19174721
[No Abstract] [Full Text] [Related]
27. Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy.
Berenbom A; Davila RM; Lin HS; Harbour JW
Eye (Lond); 2007 Sep; 21(9):1198-201. PubMed ID: 16732210
[TBL] [Abstract][Full Text] [Related]
28. Ocular distribution and toxicity of intravitreal injection of triamcinolone acetonide in normal equine eyes.
Yi NY; Davis JL; Salmon JH; Gilger BC
Vet Ophthalmol; 2008 Sep; 11 Suppl 1():15-9. PubMed ID: 19046265
[TBL] [Abstract][Full Text] [Related]
29. Rituximab and chlorambucil as first-line treatment for low-grade ocular adnexal lymphomas.
Rigacci L; Nassi L; Puccioni M; Mappa S; Polito E; Dal Pozzo S; Alterini R; Carrai V; Puccini B; Bosi A
Ann Hematol; 2007 Aug; 86(8):565-8. PubMed ID: 17483948
[TBL] [Abstract][Full Text] [Related]
30. Safety of intravitreal ketorolac and diclofenac: an electroretinographic and histopathologic study.
Kim SJ; Adams NA; Toma HS; Belair ML; Thorne JE; Green WR; Jabs DA
Retina; 2008 Apr; 28(4):595-605. PubMed ID: 18398362
[TBL] [Abstract][Full Text] [Related]
31. Rituximab in primary conjunctiva lymphoma.
Zinzani PL; Alinari L; Stefoni V; Loffredo A; Pichierri P; Polito E
Leuk Res; 2005 Jan; 29(1):107-8. PubMed ID: 15541482
[TBL] [Abstract][Full Text] [Related]
32. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma.
Leonard JP; Link BK; Emmanouilides C; Gregory SA; Weisdorf D; Andrey J; Hainsworth J; Sparano JA; Tsai DE; Horning S; Krieg AM; Weiner GJ
Clin Cancer Res; 2007 Oct; 13(20):6168-74. PubMed ID: 17947483
[TBL] [Abstract][Full Text] [Related]
33. The effect of intravitreal triamcinolone on intraocular pressure.
Kramar M; Vu L; Whitson JT; He YG
Curr Med Res Opin; 2007 Jun; 23(6):1253-8. PubMed ID: 17559723
[TBL] [Abstract][Full Text] [Related]
34. Toxicity of a biodegradable microneedle implant loaded with methotrexate as a sustained release device in normal rabbit eye: a pilot study.
Palakurthi NK; Correa ZM; Augsburger JJ; Banerjee RK
J Ocul Pharmacol Ther; 2011 Apr; 27(2):151-6. PubMed ID: 21323470
[TBL] [Abstract][Full Text] [Related]
35. Effect of intravitreal triamcinolone acetonide in the treatment of experimental Staphylococcus epidermidis endophthalmitis.
Hosseini H; Mehryar M; Eghtedari M; Ahmadi F; Nowroozizadeh S
Curr Eye Res; 2009 Feb; 34(2):145-51. PubMed ID: 19219686
[TBL] [Abstract][Full Text] [Related]
36. Effects of intravitreal dispase on vitreoretinal interface in rabbits.
Zhu D; Chen H; Xu X
Curr Eye Res; 2006 Nov; 31(11):935-46. PubMed ID: 17114119
[TBL] [Abstract][Full Text] [Related]
37. ECOG 4402: randomized phase III-trial comparing two different rituximab dosing regimens for patients with low tumor burden indolent non-Hodgkin's lymphoma.
Williams ME
Curr Hematol Rep; 2004 Nov; 3(6):395-6. PubMed ID: 15496271
[No Abstract] [Full Text] [Related]
38. Toxicity of intravitreal antiviral drugs.
Pulido JS; Palacio M; Peyman GA; Fiscella R; Greenberg D; Stelmack T
Ophthalmic Surg; 1984 Aug; 15(8):666-9. PubMed ID: 6483372
[TBL] [Abstract][Full Text] [Related]
39. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results.
Medeot M; Zaja F; Vianelli N; Battista M; Baccarani M; Patriarca F; Soldano F; Isola M; De Luca S; Fanin R
Eur J Haematol; 2008 Sep; 81(3):165-9. PubMed ID: 18510702
[TBL] [Abstract][Full Text] [Related]
40. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias.
Rao A; Kelly M; Musselman M; Ramadas J; Wilson D; Grossman W; Shenoy S
Pediatr Blood Cancer; 2008 Apr; 50(4):822-5. PubMed ID: 17570702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
